Microencapsulated mTOR Inhibitor for Age-Related Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related diseases are inadequate in delaying aging and increasing lifespan, and there is a need for effective interventions that target the underlying mechanisms of age-related disorders.
Innovation Solution
Microcapsules encapsulating an inhibitor of the mammalian target of rapamycin (mTOR) are developed, which provide chronic inhibition of the mTOR pathway, using an enteric coating for delayed release in the intestinal tract, improving therapeutic efficacy and stability, and are administered to extend lifespan and treat age-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mTOR inhibitor is administered without microencapsulation, then the treatment approach is simple, but therapeutic efficacy is reduced due to poor stability and premature release
Solution Approach 1:
The mTOR inhibitor is nested within a microcapsule structure consisting of a core component containing the inhibitor and a coating layer providing enteric protection. This nested formulation ensures the inhibitor is protected from premature release in the stomach while being delivered to the intestine for optimal therapeutic effect, thereby improving reliability without excessive complexity.
Solution Approach 2:
The microcapsule is designed with an enteric coating that prevents premature release of the mTOR inhibitor in the acidic stomach environment. The coating acts in advance to protect the inhibitor until it reaches the intestinal tract, ensuring the drug is released at the optimal location for maximum therapeutic efficacy.
2Stability of the object's composition
If mTOR inhibitor is released immediately in the stomach, then administration is simple, but the inhibitor suffers from poor stability and reduced effectiveness
Solution Approach 1:
The enteric coating is applied in advance to the microcapsule core, creating a protective barrier before administration. This preliminary protective action ensures the inhibitor maintains its stability during gastric passage and is only released in the appropriate intestinal environment, without requiring complex administration procedures.
Solution Approach 2:
The enteric coating acts as an intermediary between the acidic stomach environment and the mTOR inhibitor. This intermediate layer protects the inhibitor from degradation in the stomach while allowing controlled release in the intestine, thereby improving stability without complicating administration.
3Reliability
If the coating releases the inhibitor immediately, then the release mechanism is simple, but therapeutic efficacy is compromised due to premature release
Solution Approach 1:
The enteric coating is designed with preliminary protective properties that prevent inhibitor release in the stomach. The coating's composition and structure are established in advance to ensure delayed release occurs only when the microcapsule reaches the intestinal tract, providing controlled timing for optimal therapeutic effect.
Solution Approach 2:
The coating is designed to respond to changes in environmental parameters, specifically pH differences between the stomach and intestine. The enteric coating remains intact in the acidic stomach environment (pH 1-3) but dissolves or becomes permeable in the more neutral intestinal environment (pH 6-7.4), thereby controlling release timing through parameter changes.
Data Source
AI summary
Disclosed are microcapsules that include an inhibitor of the mammalian target of rapamycin (mTOR) within the microcapsules, and pharmaceutical compositions and kits that include the microcapsules. Also disclosed are methods for treating or preventing an age-related disease, condition, or disorder in a subject that involve administering to a subject a pharmaceutically effective amount of microcapsules that includes an inhibitor of mTOR within the microcapsules.